Importance The landscape of chronic lymphocytic leukemia (CLL) treatment has changed
considerably since the first reported assessment of minimal residual disease (MRD) by flow
cytometry in 1992. Chemoimmunotherapy (CIT) combinations have become the standard of
care for most patients, and novel targeted agents are rapidly being incorporated into the
front-line and relapsed settings. Minimal residual disease status has been shown to be a
predictor of both progression-free survival (PFS) and overall survival (OS) at the time of …